United Therapeutics (UTHR) Other Non-Current Liabilities (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Other Non-Current Liabilities data on file, last reported at $214.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 0.56% year-over-year to $214.0 million; the trailing twelve-month figure through Mar 2026 stood at $214.0 million (down 0.56% YoY), and the FY2025 full-year result was $223.2 million, up 22.7% from the prior year.
• Other Non-Current Liabilities retreated to $214.0 million in Q1 2026, from $223.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $223.2 million in Q4 2025 to a low of $67.4 million in Q3 2023.
• A 5-year average of $137.1 million and a median of $103.5 million in 2022 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities tumbled 34.88% in 2023 and surged 133.8% in 2024, its largest moves.
• Tracing UTHR's Other Non-Current Liabilities over 5 years: stood at $104.6 million in 2022, then declined by 25.62% to $77.8 million in 2023, then surged by 133.8% to $181.9 million in 2024, then rose by 22.7% to $223.2 million in 2025, then retreated by 4.12% to $214.0 million in 2026.
• Business Quant data shows UTHR's Other Non-Current Liabilities at $214.0 million in Q1 2026, $223.2 million in Q4 2025, and $214.6 million in Q3 2025.